Matrix metalloproteinase catalytic zinc site (MMP catalytic zinc site)

The catalytic zinc site of matrix metalloproteinases (MMPs) is a highly conserved structural feature essential for the proteolytic activity of this enzyme family (NIH, 2011; Biologists.com, 2024). MMPs are calcium-dependent, zinc-containing endopeptidases responsible for degrading various components of the extracellular matrix (ECM), such as collagen, elastin, and fibronectin (NIH, 2011; MDPI, 2023). The catalytic zinc ion is coordinated by three histidine residues within a conserved HEXXHXXGXXH motif, which facilitates the nucleophilic attack on the peptide bond of the substrate (NIH, 2011; NIH, 2016). In healthy tissues, MMP activity is tightly regulated to maintain tissue homeostasis, but dysregulation is a hallmark of numerous pathologies, including cancer metastasis, chronic inflammation, and cardiovascular disease (NIH, 2011; Ovid, 2022). Therapeutic strategies have historically focused on small-molecule inhibitors that chelate the catalytic zinc ion to block enzyme function (NIH, 2012; NIH, 2011). However, many early MMP inhibitors failed in clinical trials due to a lack of specificity among the 23 human MMP isoforms, leading to side effects like musculoskeletal syndrome (NIH, 2011; NIH, 2016). Modern drug discovery efforts aim to develop more selective inhibitors or monoclonal antibodies that target specific MMPs or allosteric sites to improve safety and efficacy (NIH, 2012; NIH, 2016).

Other names

MMP active siteZinc-binding site of matrix metalloproteinasesCatalytic domain of MMPsMetzincin catalytic site

Inhibition of proteolytic activity through chelation of the catalytic zinc ion or competitive/allosteric blocking of the active site.